Android app Apple app link

Truist Lowers PT on PROCEPT BioRobotics Corporation (PRCT) to $50 From $64, Keeps a Buy Rating

By Yahoo! Finance   |   1 month ago
Truist Lowers PT on PROCEPT BioRobotics Corporation (PRCT) to $50 From $64, Keeps a Buy Rating

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is a top small cap stock with high growth potential. Truist lowered its price target to $50 from $64 but maintained a Buy rating, expecting healthy Q3 results in the MedTech sector amidst potential stock volatility.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.